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Abstract
A new homozygous humanized transgenic mouse strain, HLA-A2.1+/+HLA-DP4+/+ hCD4+/+mCD42/2IAb2/2b2m2/2 (HLA-A2/
DP4), was obtained by crossing the previously characterized HLA-A2+/+b2m2/2 (A2) mouse and our previously created HLA-
DP4+/+ hCD4+/+mCD42/2IAb2/2 (DP4) mouse. We confirmed that the transgenes (HLA-A2, HLA-DP4, hCD4) inherited from
the parental A2 and DP4 mice are functional in the HLA-A2/DP4 mice. After immunizing HLA-A2/DP4 mice with a hepatitis B
DNA vaccine, hepatitis B virus-specific antibodies, HLA-A2-restricted and HLA-DP4-restricted responses were observed to be
similar to those in naturally infected humans. Therefore, the present study demonstrated that HLA-A2/DP4 transgenic mice
can faithfully mimic human cellular responses. Furthermore, we reported four new HLA-DP4-restricted epitopes derived
from HBsAg that were identified in both vaccinated HLA-A2/DP4 mice and HLA-DP4-positive human individuals. The HLA-
A2/DP4 mouse model is a promising preclinical animal model carrying alleles present to more than a quarter of the human
population. This model should facilitate the identification of novel HLA-A2- and HLA-DP4-restricted epitopes and vaccine
development as well as the characterization of HLA-DP4-restricted responses against infection in humans.
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Introduction
Protective immunity requires the effective mobilization of B
cells, cytotoxic T cells and helper T cells [1]. Major Histocom-
patibility Complex (MHC) molecules play a pivotal role in
shaping both the specificity and the functional outcome of
adaptive immune responses. The repertoire of functional T cell
receptors on CD4+ and CD8+ T cells is dependent upon the
presence of MHC molecules implicated in the positive and
negative selection of thymocytes in the thymus [2]. Moreover, the
MHC controls the activity of T cells through peripheral tolerance
mechanisms and the ability to select and present MHC-restricted
epitopes [3].
HLA-restricted epitopes was shown to be important for boosting
the effectiveness of HLA-restricted epitope-based vaccine candi-
dates. There is considerable interest in inducing specific CTLs to
prevent or control viral infections or to cure autoimmune diseases.
Promising protective antiviral immunity using CTL epitope-based
vaccines has been demonstrated in several experimental models of
infection [4]. Similarly, CD4+ T cell epitope-based vaccines have
been designed for several experimental autoimmune and patho-
genic diseases [5–8]. However, these vaccines did not induce
significant or sufficient protection in human preclinical trials. The
insufficient efficacy could be due to the lack of simultaneous
activation of specific B cells, cytotoxic T cells and helper T cells,
which is required for protective immunity [9]. Given the practical
difficulty of studying immune responses in humans, several
transgenic mouse models expressing human HLA class I or class
II molecules have been developed to map potential pathogenic
and tumoral epitopes as well as to predict human immunity
[10,11].
To facilitate the development of a new generation of candidate
vaccines and to evaluate their efficacy in vivo, a predictive
preclinical ‘‘humanized’’ transgenic mouse model that expresses
both HLA-A2 and HLA-DR1 while lacking H2-IAb and H2-b2m
was developed [12]. These mice allow for the simultaneous
evaluation of specific B cells, HLA class I-restricted CD8+ T cells
and HLA class II-restricted CD4+ T cells of human interest.
However, this humanized mouse model represents the immunity
of approximately 3–9% of the human population (30–50% for
HLA-A2.1, 6–18% for HLA-DR1) [13], thus limiting the
usefulness of this model for preclinical research.
The HLA-DP4 locus is one of the most abundant HLA alleles
worldwide (20–80% of the population), being even more abundant
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32247
than HLA-A2 (30–50%). It consists of two subtypes, DP0401 and
DP0402, which differ from each other by 3 amino acids.
Preliminary reports have shown that the presence of both
DP0401 and DP0402 occurs at a frequency of 50% in Europe,
60% in South America, 80% in North America, 60% in India,
40% in the Xinjiang district in China, 25% in Africa and 15% in
Japan [14,15]. Interestingly, some reports have suggested that
antigen presentation by HLA-DP4 molecules may be critical for
viral elimination and that such antigen presentation plays an
important role in the pathogenesis of chronic hepatitis B infection
[16,17]. These studies highlight the importance of HLA-DP4 in
the immune response to infection and in some autoimmunity
diseases [18,19]. Increasing evidence of the importance of HLA-
DP4 and its high frequency in the human population suggests that
HLA-DP4 epitope-based vaccines could induce immune protec-
tion in a large proportion of the population. However, a limited
number of HLA-DP4-restricted epitopes have been documented
for pathogenic infection [20–25] and tumors [26–28].
In this study, we describe a homozygous humanized HLA-
transgenic mouse strain, HLA-A2.1+/+HLA-DP4+/+hCD4+/+
mCD42/2IAb2/2b2m2/2 (HLA-A2/DP4), which was produced
by crossing the previously characterized HLA-A2+/+b2m2/2 (A2)
mouse [29] and an HLA-DP4+/+hCD4+/+mCD42/2IAb2/2 (DP4)
mouse strain [30] that we established in our laboratory. We then
confirmed the phenotypes and immunological activities characteristic
of the transgenes (HLA-A2 and HLA-DP4) inherited from the
parental HLA-A2 andHLA-DP4mice. Finally, we screened forHLA-
DP4-restricted epitopes derived from HBV envelop protein using the
HLA-A2/DP4 mouse, and we identified 4 new HLA-DP4-restricted
epitopes (S256–268, S326–338, S347–358 and S352–364) that could trigger T
helper cell responses similar to those observed in vaccinatedHLA-A2/
DP4 mice and HBV-vaccinated DP4-positive human donors. Our
results demonstrate that the HLA-A2/DP4 mouse represent a
promising preclinical research animal model that shares immunolog-
ical traits with approximately one-quarter of the human population
(30–50% for HLA-A2 and 20–80% for HLA-DP4). Thus, this animal
model should facilitate the identification of novel HLA-A2- and/or
HLA-DP4-restricted epitopes that could be further developed as
biomarkers and vaccine components.
Materials and Methods
Generation of transgenic mice
HLA-DP4/hCD4 transgenic H-2 class II (IAb)/mCD4-KOmice
[30] were obtained at the INSERM by crossing our established
HLA-DP4-transgenic mice (HLA-DP4+/+ hCD4+/+mCD42/2)
with H-2 class II (IAb)-KO (IAb2/2) mice. The HLA-A2.1-
transgenic mice, expressing a chimeric monochain (HHDmolecule:
a1–a2 domains of HLA-A2.1, a3 to the cytoplasmic domains of H-
2 Db, linked at its N-terminus to the C-terminus of human b2m by a
15-amino-acid peptide linker), were created in Pasteur Institute
[29]. HLA-A2.1 (HHD)-transgenic H-2 class I (b2m)-KO and
HLA-DP4/hCD4-transgenic H-2 class II (IAb)/mCD4-KO mice
were intercrossed. After six generation, the heterozygote progeny
with HLA-A2.1-HLA-DP4- hCD4 were selected to continue
intercrossing till mCD42/2IAb2/2b2m2/2 mice were obtained.
Finally, HLA-A2.1+/+HLA-DP4+/+ hCD4+/+ mice with the
background of mCD42/2IAb2/2b2m2/2 mice were obtained
and used for the experiments described in this report. Mice were
bred in the animal facilities at INSERM U1014 (Paris, France)
under barrier conditions and provided with commercial mouse
chow and water ad libitum. All experiments involving mice were
performed according to approved protocols and the guidelines of
the animal facility of Hospital Paul Brousse (Villejuif, France) under
agreement number 94-076-32 and permit number 94–241 from the
Directorate of Veterinary Services.
Genotype identification
The HLA-A2.1 (HHD)-transgenic H-2 class I-KO and DP4-
transgenic H-2 class transgenic II-KO (IAbb) mice were identified
by PCR. Mice genomic DNA was extracted using genomic DNA
isolation protocols. Briefly, tails were digested by incubation with
100 mM NaCl, 50 mM Tris-HCl, pH 7.2, 100 mM EDTA, 1%
SDS and 0.5 mg/mL proteinase K (Merck, Darmstadt, Germany)
overnight at 56uC, followed by the addition of 250 mL of saturated
NaCl solution and isopropanol precipitation. Pellets were washed
2 times with 70% ethanol and resuspended in 100 mL deionized
water. After homogenization of the DNA concentration, PCR was
used to amplify transgenes with different pairs of forward and
reverse primers, as follows:
HHD: 59CATTGAGACAGAGCGCTTGGCACAGAAGCA-
G39, 59GGATGACGTGA GTAAACCTGAATCTTTGGAGTA-
CGC; DP04a: 59TAATACAAAGTCTGCAGC TGGC39, 59AGC-
AATGTTAGCCAGCC39; DP04b: 59GGGATTGGAAAGAGG-
CT C39, 59GCACTGCCCGCTTCTCC39; hCD4: 59TCAGTG-
CAATGTAGGAGTCCAA G 39, 59CACGATGTCTATTTTG-
AACTCCAC39; mCD4: 59GGAGTTGTGGGTGTT CAAAG-
TG39, 59AGAGTTGCTATCCAAGGTCAGGG39; 59GCTTCC-
TCGTGCTTT ACGGTATC39; b2m: 59CTGAGCTCTGTTT-
TCGTCTG39, 59CTTAACTCTGCA GGCGTATG39; 59CCT-
GCCGAGAAAGTATCCA39; and Iab: 59TTCGTGTACCAGTT-
CATGGG39, 59TAGTTGTGTCTGCACACCGT39, 59CCTGC-
CGAGAAAGTATCCA 39.
FACS analysis
Splenic cells were separated by Ficoll gradients (GE Life-
sciences, Uppsala, Sweden). Cytofluorometry studies were per-
formed on splenocytes using PE-conjugated W6/32 (anti-HLA-
ABC; eBioscience, San Diego, CA). Analysis of MHC class II
molecule expression was conducted after saturation of Fc receptors
with the 2.4G2 mAb using FITC-labeled anti-HLA-DP (B7/21)
and PE-labeled anti-CD19. CD4+/CD8+ positive lymphocytes
that were first labeled with APC anti-CD3 (BD Biosciences, San
Diego, CA, USA). Portions of the single mCD8+, mCD4+ and
hCD4+ lymphocytes were labeled using PE-labeled anti-mouse
CD8, FITC-labeled anti-mouse CD4, and PECy7-labeled anti-
human CD4. Wild-type C57BL/B6 mice were chosen as a
control.
DNA immunization
The hepatitis DNA vaccine pCMV-S2.S [31] was used to verify
the consistency in the in vivo cellular responses between the
transgenic mice and humans. At the age of 8 weeks, transgenic
mice were pre-immunized with cardiotoxin. After 5 days, the mice
were immunized 3 times intramuscularly at 10-day intervals, each
time with a 100-mg DNA vaccine injection. Ten days after the last
immunization, the mice were used for further analyses.
ELISA assay
Sera from immunized mice were individually assayed by ELISA
[31] on either purified HBsAg or preS2 synthetic HBs109–134
peptide. After blocking with PBS supplemented with 0.1% Tween-
20, 10% FCS and washings three times, bound antibodies were
detected with horseradish peroxidase-labeled anti-mouse IgG
(Serotec, Cergy-Saint-Christophe, France). Antibody titers (means
of at least three determinations) were determined by the serial end-
point dilution method.
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ELISPOT assay
An ELISPOT assay was implemented to detect IFN-c secreted
by CD8+ T lymphocytes. Briefly, membrane-backed 96-well
ELISPOT plates (Millipore, Bedford, MA) were coated with
anti-IFN-c mAb (Diaclone, Besancon, France) overnight at 4uC
and then blocked with 1% skim milk. CD4-lymphocyte-depleted
cells (26105/well) were added to each well, cultured with 20 mg/
mL synthetic peptides and incubated for 20 h at 37uC under 5%
CO2. The IFN-c-secreting cells were captured by coating with
anti-IFN-c mAb and detected by incubation with biotinylated
anti-mouse IFN-cAb (Diaclone) for 90 min at 37uC, followed by
incubation with streptavidin-HRP for 1 h. Finally, the plates were
developed using substrate BEC (Diaclone, ready to use), washed,
and dried. Spots were counted using an ELISPOT reader (CTL,
Germany).
Proliferation assay
Ten days after the final immunization, splenocytes were RBC-
depleted, submitted to a Ficoll gradient, and adjusted to 106106
cells/mL (56105cells/well) [12]. Splenocytes were co-cultured
with peptide-pulsed (20 mg/mL) in HL1 serum-free medium
supplemented with 10 mM HEPES, 1 mM sodium pyruvate,
561025 M 2-mercaptoethanol, 100 IU/mL penicillin and 100 mg
streptomycin for 72 h at 37uC in 5% CO2. One microcurie of
[3H]thymidine was added to each well 16 hours before the cells
were harvested using a TOMTEC collector (Perkin Elmer Applied
Biosystems), and the incorporated radioactivity was measured
using a micro-b-counter (Perkin Elmer Applied Biosystems). The
results are given as the stimulation index (SI) = cpm with specific
peptide/cpm with control peptide (Mag-3243–258 KKLLTQHF
VQENYLEY) [32].
HLA-DP4 specific binding assay
HLA-DP4 binding assays were performed as described
elsewhere [14]. In brief, they were performed in 10 mM
phosphate, 150 mM NaCL, 1 mM n-dodecyl b-D-maltoside,
10 mM citrate, and 0.003% thimerosal (PH 5) buffer with
10 mM of bOxy271-287 peptide, an appropriate dilution of
HLA-DP4 molecules (,0.1 mg/mL), and serial mid-dilutions of
competitor peptides. After 24 h incubation at 37uC, samples were
neutralized and applied to B7/21-coated plates for 2 h. Bound
biotinylated peptide was detected by means of streptavidin-alkaline
phosphatase conjugate (Amersham, Little Chalfont,UK) and 4-
methylumbelliferyl phosphate substrate(Sigma-Aldrich). Emitted
fluorescence was measured at 450 nm upon excitation at 365 nm
in a victor II spectrofluorometer (PerkinElmer Instruments, Les
Ulis, France). Data were expressed as the peptide concentration
that prevented binding of 50% of the labeled peptide(IC50). IC50
values of the Oxy271–287 peptides served as reference in each
experiment.
Human T cell proliferation assays
Human peripheral blood mononuclear cells (PBMCs) were
incubated with the HBsAg peptides and the positive control
peptide at 20 mg/mL in T cell medium containing 7.5% AB serum
for 5 days and pulsing with one microcurie of [3H]thymidine for
16 hours before harvesting. Wells were harvested using the
TOMTEC collector (Perkin Elmer Applied Biosystems), and the
incorporated radioactivity was measured using a micro-b counter
(Perkin Elmer Applied Biosystems). The results are given as the
stimulation index (SI) = (cpm with specific peptide)/(cpm with
control peptide).
Results
Cell surface expression of MHC molecules in HLA-A2/DP4
mice
HLA-A2/DP4 mice were obtained by crossing the parental
HLA-A2+/+b2m2/2 (A2) mice and HLA-DP4+/+hCD4+/+
mCD42/2IAb2/2 (DP4) mice. The genotype and cell surface
expression of HLA-A2.1 and HLA-DP4 were confirmed on
splenocytes from the HLA-A2/DP4 mice by PCR (data not
shown) and flow cytometry. As illustrated in Figure 1A, HLA-A2.1
expression was observed in HLA-A2/DP4 mice, whereas no
expression was detected in wild-type C57BL/B6 mice. As shown
in Figure 1B and 1C, HLA-DP4 expression was observed only in
the HLA-A2/DP4 mice(Figure 1C), however, no HLA-DP4
expression was detected as expected (Figure 1B). In addition,
Figure 1. Flow cytometric analysis of HLA-A2 and HLA-DP4 expression of transgenic molecules. (A) Splenocytes from HLA-A2/DP4 (bold
histogram) and wild-type C57BL/B6 (shadowed histogram) mice were isolated and stained with PE-labeled anti-HLA-ABC mAb to observe the HLA-A2
expression. PE-labeled mouse IgG2a, k mAb was used as isotype control (thinned histogram) for staining HLA-A2/DP4 mouse. (B) Splenocytes from
wild-type C57BL/B6 mice (Figure 1B) and HLA-A2/DP4 (Figure 1C) were isolated and stained with PE-labeled anti-CD19 and FITC-labeled anti-HLA-DP
mAb to observe the HLA-DP4 expression.
doi:10.1371/journal.pone.0032247.g001
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DP4+CD192 T lymphocytes were further analyzed by staining
PEcy7-labeled anti-CD11b and FITC-labeled anti-CD11c in
Figure S1.
Peripheral CD8+ T and CD4+ T lymphocytes in HLA-A2/
DP4 mice
Splenic CD4+ and CD8+ T cell numbers were determined by
immunostaining and flow cytometry analysis. T lymphocytes were
labeled with APC-conjugated anti-CD3+ antibody and then with
PE-conjugated anti-mCD8+, FITC-conjugated anti-mCD4+ and
PECy7-conjugated anti-hCD4+ antibodies, as illustrated in
Figures 2–3.
The expression of HLA-A2.1 and HLA-DP4 molecules allowed
for the selection of peripheral CD8+ and CD4+ T cells in HLA-
A2/DP4 mice. As shown in Figure 2, around 2.3% CD8+ T cells
(Figure 2A and 2C), compared with 0.6–1% CD8+ T cells in b2-
microglobulin (b2m)-deficient MHC class I-deficient mice [29];
there were 89–90% CD4+ T cells (Figure 3D and 3E) compared
with 2–3% CD4+ T cells in the H-2 class II-KO mice [33]. In
comparison, wild-type C57BL/B6 mice possess around 17.2%
CD8+ T cells (Figure 2B and 2C) and 77% CD4+ T cells
(Figure 3C) in CD3+ T cells.
It has been reported that the differentiation of immature
CD4+CD8+ double-positive T cells into CD4+ T cells in the
thymus is highly dependent on the expression of human CD4
(hCD4) [34]. As shown in Figures 3D and 3E, 89–90% of CD4+ T
cell expressed hCD4, and 0–0.3% of the remaining cells exhibited
nonspecific staining with FITC-labeled anti-murine CD4 (mCD4)
in HLA-A2/DP4 mice (Figure 3A and 3B). In contrast, 77.3% of
the CD4+ T cells in wild-type C57BL/B6 mice C57BL/B6 mice
express mCD4 (Figure 3C) rather than hCD4 (0.03%) (Figure 3F).
In addition, flow cytometric analysis was also used to observe the
percentage of Treg cells in CD4+ T cells in Figure S2.
Humoral responses and HLA-A2-restricted responses in
HLA-A2/DP4 mice
To evaluate the immunological potential of HLA-A2/DP4 mice
and their ability to predict human responses, we compared the
humoral response and the immunodominant HLA-A2-restricted
response in the HLA-A2/DP4 mice with the responses that have
been previously reported for naturally infected patients or
immunized humans. We immunized the HLA-A2/DP4 mice with
an HBV DNA vaccine that encodes two HBV envelope proteins
(preS2 and S proteins). These two proteins can self-assemble into
particles carrying HBsAg, and they are the two protein
components of currently used vaccine against hepatitis B.
To show that the CD8+ T cells in the periphery of HLA-A2/
DP4 mice are functionally restricted by transgenic human class I
molecules (as reported for the transgenic HLA-A2 mice [29]), we
examined the HBsAg-specific CD8+ CTL responses by monitoring
the immunodominant HLA-A2.1-restricted epitope responses
directed against HBsAg348–357 [35] and HBsAg335–343 [36]
epitopes. The results showed that after immunization with the
pCMV-S2.S HBV DNA vaccine, the transgenic mice exhibited
HBsAg-specific humoral responses (Figure 4A) and HLA-A2-
restricted CD8+ T cell responses (Figure 4B). The immunodomi-
nant HLA-A2.1-restricted response is directed against the
HBsAg348–357 and HBsAg335–343 epitopes, whereas in wild-type
C57BL/B6 mice, the H-2 Kb-restricted HBsAg-specific CTL
response is directed against the HBsAg371–378 epitope [37]. To
determine whether HLA-A2/DP4 mice mount the same HLA-A2-
restricted CTL response as HLA-A2/DR1 mice and humans,
splenic T cells were stimulated with the relevant HLA-A2.1-
restricted peptides, HBsAg348–357, HBsAg335–343 and a control
(HBsAg371–378, H-2 K
b-restricted), and the secretion of IFN-c was
measured as a read-out. As expected, HBsAg DNA immunization
elicited a significant CTL response against HBsAg348–357 and
HBsAg335–343, and there was no response against HBsAg371–378
(Figure 4B). The results demonstrate that CD8+ T cell responses in
HLA-A2/DP4 mice are HLA-A2-restricted and are similar to the
CD8+ CTL response after immunization of HLA-A2/DR1
transgenic mice with the same vaccine [12].
HLA-DP4-restricted responses in HLA-A2/DP4 mice
To evaluate the behavior of CD4+ T cells in HLA-A2/DP4
mice, we immunized the mice with a hepatitis B virus DNA
vaccine, pCMV-S2.S, by intramuscular injection. H2-class II-
deficient mice were used as a control [33]. As shown in Figure 5A,
HBs protein- and PreS2 antigen-specific antibodies were induced
in HLA-A2/DP4 transgenic mice (solid column) at 10 days after
the third immunization. Conversely, no antigen-specific antibodies
were detected in H2-class II-deficient mice. This result demon-
strates that potent humoral responses require the help of CD4+ T
cells.
Figure 2. Flow cytometric analysis of peripheral CD8+ T lymphocytes. Splenocytes from HLA-A2/DP4 (Figure 2A) and wild-type C57BL/B6
mice (Figure 2B) were isolated and CD3+ T cells were gated by staining APC-conjugated anti-CD3 mAb and CD8+ T cells were gated by staining PE-
conjugated anti-mCD8 mAb. Frequencies of CD8+ T cells among total CD3+ T cells from 6 mice of each group were shown in Figure 2C.
doi:10.1371/journal.pone.0032247.g002
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In the in vitro proliferation assays (Figure 5B), HBsAg DP4-
restricted CD4+ T cells responded to whole HBs antigen and to
the previously described HLA-DP4-restricted peptide, S181–S192
[20]. No responses were observed in the H2-class II-deficient mice
(hollow column) or to the control HLA-DP4-restricted peptide,
Mage-3243–258 [32]. The results demonstrate that HBsAg could
induce the HLA-DP4-restricted proliferation of CD4+ T cells in
HLA-A2/DP4 transgenic mice.
Identification of novel HLA-DP4 epitopes that respond to
the HBsAg DNA vaccine
Having documented that the HLA-A2/DP4 mice could
respond to HBsAg, a previously described DP4-restricted epitope,
we next sought to identify novel HLA-DP4-restricted epitopes in
the HBs envelope protein. The immunogenicity of both T helper
and CTL epitopes are related to their MHC-binding capacities,
with good T helper inducers generally having a high affinity for
MHC class II molecules. We therefore scanned the hepatitis B
envelope protein based on the HLA-DP4 peptide-binding motif
[38] and selected 11 candidate peptides. The affinities for each of
the candidate peptides were evaluated (Table 1). We also
immunized HLA-A2/DP4 transgenic mice intramuscularly with
the pCMV-S2.S DNA vaccine. The splenocytes derived from the
primed mice were separated and then stimulated in vitro with 12
HLA-DP4-restricted peptides, including the HLA-DP4-restricted
epitope HBs181–192. The peptides S109–121, S256–268, S326–
338, S347–358 and S352–364 induced proliferative responses in
HLA-A2/DP4 mice, whereas no responses were observed in the
control H-2 class II-deficient mice. Thus, the HLA-A2.1+/+HLA-
DP4+/+hCD4+/+ mCD42/2 IAb2/2b2m2/2 mice allowed us to
identify 5 novel HLA-DP4-restricted epitopes from the hepatitis B
envelope protein.
HLA-DP4-restricted CD4+ T cell responses in vaccinated
humans
To determine whether the epitopes that we identified in the
HLA-A2/DP4 mice were relevant for human immune responses,
PBMCs from 6 HLA-DP4+ donors, including 4 donors who had
been immunized against HBV and 2 donors who were never
immunized, were utilized to analyze their HLA-DP4-restricted
CD4+ T cell responses. The results of the proliferation assays
(Table 2) showed that three out of four immunized subjects
responded to the reported Celis (S181–S192) peptide. The
responses of two donors were directed against the S326–338 and
S256–268 peptides. One response was observed against the S352–
364 and S347–358 peptides. No significant responses against the
S109–121 peptide (which was derived from the S2 part of the
antigen) were observed in the four donors who had received the
Figure 3. Flow cytometric analysis of peripheral mCD4+ and hCD4+ T lymphocytes. Splenocytes from HLA-A2/DP4 (Figure 3A, 3B, 3D and
3E) and wild-type C57BL/B6 (Figure 3C and 3F) mice were isolated and CD3+ T cells were gated by staining with APC-conjugated anti-CD3 mAb.
Meanwhile, FITC-conjugated anti-mCD4 and PECy7-conjugated anti-hCD4 antibodies were simultaneously used to observe the mCD4 and hCD4
expression in HLA-A2/DP4 and WT C57BL/B6 mice.
doi:10.1371/journal.pone.0032247.g003
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HBV vaccine. All together, four out of five newly identified DP4-
restricted HBs epitopes were functional to detect specific T cell
responses in vaccinated humans.
Discussion
In the present study, we developed an HLA transgenic mouse
model that lacked an H-2 antigen system. As we mentioned above,
this newly created HLA-A2/DP4 transgenic mouse model
combines the most frequent HLA class I allele, A*0201, with the
most frequent class II allele, HLA-DP4. At least a quarter of the
Caucasian population (which is ,50% positive for HLA-A*0201
and,76% for HLA-DP4 [13]), for example, carries the HLA-A2/
DP4 genotype. Thus, this mouse model could predict human
cellular responses for a larger proportion of the human population
than our previously established HLA-A2/DR1 mouse model.
According to human allele frequency statistics, DP4 is the most
abundant allele in the world, and it shares a motif with other
subtypes DPB1*0101, DPB1*0501 and DPB1*0201 [39] as DR
and DQ superfamilies. Furthermore, the HLA-DP4 allele has
become increasingly valuable in preclinical research. Accumulat-
ing evidence has proven that DP4 is important in immunity, and it
is a key allele in preventing viral infection, autoimmunity and
transplant rejection [40]. A recent study indicated that DP4 is a
protective allele in preventing chronic infection with HBV. Other
studies have shown that the presence of DP4 is correlated with
diabetes and multiple sclerosis [18,19]. These studies were based
on statistical analyses, and further explanation of this mechanism is
required. However, polymorphisms among different species and
individuals as well as a lack of human samples have hampered
HLA studies leading to DP-related research, and there are
surprisingly few mouse models for DP.
In the HLA-A2/DP4 mouse model, the development of a
repertoire of CTLs and T helper cells and the mobilization of
effector cells in the periphery should be restricted to HLA
molecules rather than murine H-2 molecules. We confirmed
HLA-A2 and DP4 molecules were expressed on the cell surface in
HLA-A2/DP4 mouse model. With the regulation of HLA
molecules, there is a normal population of T lymphocytes in the
periphery. Even through the percentage of CD8 T cells is
relatively low in HLA-A2/DP4 mice, this observation in
accordance with our previously reported HLA-A2/DR1 mice in
2004. Even in this case, expression of transgenic HLA-A2.1
molecule led to an increase in the size of the peripheral CD8+ T
cell population, which reached 2–3% of the total splenocytes in
HLA-A2/DR1 mice, compared to 0.6–1% in b2m-KO MHC-I
deficient mice [12]. Furthermore, this phenomenon had been
discussed and several studies on HBV and HIV proved that the
low percentage for CD8+ T cell doesn’t significantly affect the
usage of HLA-A2/DR1 mice in immunological analysis [41,42].
Then, we observed the humoral and HLA-restricted immune
responses in this mouse model by studying HBV DNA
immunization. After DNA immunization, we could detect a
significant humoral response against target proteins. Meanwhile,
we confirmed that both the CTL response and the Th response
were HLA-restricted responses rather than H-2 restricted
Figure 4. HBs-specific antibody and cytotoxic responses. (A) Sera were collected 10 days after the third immunization, and the titers of the
antibody (IgG) against HBs particles in the immunized mice (solid bar) were determined and compared with the mean responses of six PBS-
immunized mice (hollow bar) in an ELISA assay. (B) HBs epitope-specific IFN-c production by CTLs was determined by measuring response to the
HLA-A2-restricted epitopes HBsAg348–357 and HBsAg335–343 and to the H-2 Kb-restricted epitope HBsAg371–378 in immunized mice (solid bar)
and PBS-immunized mice (hollow bar).
doi:10.1371/journal.pone.0032247.g004
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responses. Our results demonstrated that these mice exhibit HLA-
DP4 responses similar to those observed in humans, and the mice
should be useful, not only for the identification of new HLA-DP4-
restricted epitopes and assessing the efficiency and safety of novel
vaccines but also for analysis of the cooperation between HLA-A2
and HLA-DP4 and their contribution to immunity.
Compared with HLA-A2, DP4 restricted epitopes of HBV are
rarely reported. Therefore, mapping immunodominant DP4
epitopes will be of great value for vaccine applications. Given
that one epitope identified in HLA-A2/DP4 transgenic mice did
not induce a significant response in vaccinated humans, it is
possible that competition among different HLA-class II molecules
in human body results in the selection of immunodominant
epitopes that would be concentrated on the human MHC
molecules in the humanized mice. In a natural situation, several
HLA genes are codominantly expressed in the ER, and they can
compete for overlapping epitopes [43–45]. Thus, the set of
peptides associated with an HLA molecule can be influenced by
the presence of other HLA molecules. In addition, we speculate
that other factors may have influenced the results, such as Treg
Table 1. DP4 epitopes binding ability and proliferative response in HLA-A2/DP4 mice.
Anchors Exp Obs SI
Positions 1 6 9 IC50(nM) IC50(nM) HLA-A2/DP4 H2 CII KO
S109–121 MQWNSTTFHQTLQ 40 144 2 1
S165–177 ENITSGFLGPLLV 180 .10000 1 1
S181–192 GFFLLTRILTIPQ 70 2 2–3 1
S197–209 SWWTSLNFLGGTT 300 737 1 1
S256–268 FLLVLLDYQGMLP 120 .10000 2–3 1
S318–331 SSWAFGKFLWEWA 110 46 1 1
S319–331 WAFGKFLWEWASA 160 221 1 1
S326–338 WEWASARFSWLSL 10 77 2 1
S347–358 VGLSPTVWLSVI 120 30 2–3 1
S352–364 TVWLSVIWMMWYW 28 .1000 2–3 1
S362–374 WYWGPSLYSILSP 40 952 1 1
S376–388 LPLLPIFFCLWVY 60 626 1 1
Twelve HLA-DP4-restricted epitopes were predicted by scanning the entire HBs protein and were synthesized. Exp IC50 (nM) represents the predicted affinities
according to algorithms, while Obs (nM) represents the affinities obtained from MHC class II binding assays. [3H]thymidine incorporation assays were used to measure
the proliferation of CD4+ T cells from DNA-vaccine-immunized HLA-A2/DP4 and H-2 class II-deficient mice stimulated with the twelve synthesized peptides, including
the previously reported epitope, S181–192. Exp = Expected, Obs =Observed, SI, stimulation index.
doi:10.1371/journal.pone.0032247.t001
Table 2. Proliferative response in DP4-positive donors.
DP4+ HBV vaccinated (SI)
DP4+ unvaccinated
(SI)
Positions Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
S109–121 1.1 0.9 0.8 1.0 0.8 0.9
S181–192* 7.2 3.6 0.8 3.1 0.8 1.1
S256–268 2.4 1.4 0.4 3.1 0.7 1
S326–338 1.4 2.3 0.5 3.5 1 1
S347–358 1.2 2.2 0.6 1.1 1 0.9
S352–364 1.2 3.1 0.7 1.6 1 0.7
*S181–S192 peptide was used as positive control.
The proliferation of CD4+ T cells in 4 HBV vaccinated and 2 unvaccinated HLA-
DP4+ donors after in vitro stimulation with 5 newly identified HLA-DP4-
restricted epitopes and one positive control peptide S181–S192. SI, stimulation
index.
doi:10.1371/journal.pone.0032247.t002
Figure 5. HBs-specific antibody and proliferative response. (A)
The titers of antibody (IgG) from HLA-A2/DP4 transgenic mice (solid
bar) and H-2 class II-deficient mice (hollow bar) against HBs particles
and the preS2109–134 peptide were determined using an ELISA assay
(Figure 5A). (B) The HLA-DP4-restricted proliferation of CD4+ T cells from
HLA-A2/DP4 transgenic mice (solid bar) and H-2 class II-deficient mice
(hollow bar) after stimulation with HBs particles, the previously
described HBV DP4 restricted peptide, S181–S192, or the control HLA-
DP4-restricted epitope, Mag-3243–258 (Figure 5B).
doi:10.1371/journal.pone.0032247.g005
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cells; it is reported that Tregs epitopes can suppress the
proliferation of other T cells after peptide stimulation in vitro
[46] but this speculation need further verification.
In conclusion, we reported the creation of a new HLA-A2/DP4
mouse model that can be reliably used to identify immunodomi-
nant epitopes in humans and to rank their ability to prime CTLs
and T helper cells. This mouse model thus represents a promising
surrogate model for studying the immune responses before human
preclinical trials.
Supporting Information
Figure S1 Flow cytometric analysis of HLA-DP4 expres-
sion of transgenic molecules. Splenocytes from wild-type
C57BL/B6 mice (Figure S1A) and HLA-A2/DP4 (Figure S1B)
were isolated and stained with APC-labeled anti-CD19 and PE-
labeled anti-HLA-DP mAb to observe the HLA-DP4 expression.
In addition, DP4+ CD192 T lymphocytes were further analyzed
by staining PEcy7-labeled anti-CD11b and FITC-labeled anti-
CD11c(Figure S1C).
(TIF)
Figure S2 Flow cytometric analysis of the percentage of
Treg cells. Splenocytes from HLA-A2/DP4 and wild-type
C57BL/B6 mice were isolated and CD3+ T cells were gated by
staining with FITC-labeled anti-CD3 mAb. Meanwhile, PEcy7-
labeled anti-hCD4 mAb and APC-labeled anti-Foxp3 mAb were
simultaneously used to observe the Treg frequency in hCD4+ T
cells of HLA-A2/DP4 mice(Figure S2A, S2B, and S2C), while
PECy7-conjugated anti-mCD4 mAb and APC-labeled anti-Foxp3
mAb were simultaneously used to observe the Treg frequency in
mCD4+ T cells of WT C57BL/B6 mice(Figure S2D, S2E, and
S2F).
(TIF)
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